Two former Pfizer sales representatives failed to persuade a federal appeals court to reinstate their False Claims Act lawsuit against Pfizer Inc. (United States ex rel. Booker v. Pfizer, Inc., 2017 BL 26377, 1st Cir., No. 16-1805, 1/30/17).
The U.S. Court of Appeals for the First Circuit yesterday affirmed two trial court rulings rejecting allegations brought by whistle-blowers Alex Booker and Edmund Hebron that the drugmaker used off-label promotions and a sham physician speaker program to push sales of its schizophrenia drug, Geodon. The appeals court agreed with a trial ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.